Novo Nordisk Fellowships
Novo Nordisk Postdoctoral Fellowship Programme at Karolinska Institutet
This fellowship programme aims to support the development of a new generation of exceptional young diabetes and metabolism researchers, to become future leaders in the field, while further developing scientific excellence within these areas ultimately improving the lives of patients.
Based at Karolinska Institutet, Fellows will undertake cutting edge research projects, mentored by front-line researchers in the field of diabetes and metabolism. In addition, it is anticipated that during the course of the fellowships, fellows will have the opportunity to spend approximately 3 months in the research laboratories at Novo Nordisk in Copenhagen. Thus, Fellows will gain insight into research conducted in both academia and industry. In order to increase coherence around the Fellowship programme, a number of events will be held throughout the year such as high profile lectures, symposia, etc. which the fellows will attend, both at Karolinska Institutet and at Novo Nordisk in Copenhagen.
- The postdoctoral research fellowships are aimed at early career researchers with a basic science background.
- Fellowships are fully funded for a 3-year period providing salary as well as travel allowance for the fellow.
- The fellowship programme is open to outstanding candidates of any nationality.
Workshops and meetings
Programs from previous KI-Novo Nordisk workshops:
Dr Osman Ahmed
Dr Thomas Ebert
Principal Investigator: Prof Juleen Zierath, Dept of Molecular Medicine and Surgery
Dr Ilke Sen
Dr Lars Paeger
Dr Noah Moruzzi
Dr Kelvin Kwok
Programme Steering Committee
Karolinska Institutet members
Prof. Juleen Zierath, Clinical Physiology. Steering Committee Chairman
Prof. Anders Gustafsson, Vice President of KI
Prof. Nancy Pedersen, Medical Epidemiology
Prof. Barbara Canlon, Hearing Physiology
Novo Nordisk members
Prof. Peter Kurtzhals, Chief Scientific Advisor, Novo Nordisk R&D
Prof. Daniel Brunicardi Timmermann, Head of Innovation, Global Drug Discovery
Prof. Mads Tang-Christensen, Corporate Vice President, Obesity Research